Sinopharm: the Envida NSCLC phase III clinical trial for adjuvant/neoadjuvant therapy has completed the enrollment of all subjects.

On May 22, Sinopharm Group's anti-tumor innovative drug company Sinopharm Cancer Bio announced that the Envalu monoclonal antibody injection, a cooperative project with Siredee Medicine and Coning Jerri Biopharmaceutical, has completed enrollment of all subjects in a randomized, controlled, double-blind, multicenter Phase III clinical study for the neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer.